Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

470 Views

Poster Session: COVID-19: Infection Prevention

1918 - Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

Jesus Abraham Simón Campos, MD

DIRECTOR
Köhler & Milstein Research/Hospital Agustín O’Horán
Mérida, Yucatan, Mexico

Co-Author(s)

DA

Douglas Arbetter, MPH

AstraZeneca
Waltham, Massachusetts, United States
HM

Hugh Montgomery, MD

University College London
London, England, United Kingdom
FH

F.D. Richard Hobbs, FMedSci

Head of Primary Care
University of Oxford
Oxford, England, United Kingdom
FP

Francisco Padilla, MD

Centro de Investigación en Cardiología y Metabolismo
Guadalajara, Jalisco, Mexico
KK

Kenneth Kim, MD

ARK Clinical Research
Long Beach, California, United States
KS

Katie Streicher, PhD

AstraZeneca
Gaithersburg, Maryland, United States
AT

Alison Templeton, PhD

AstraZeneca
Cambridge, England, United Kingdom
RV

Rolando M. Viani, PhD

AstraZeneca
Gaithersburg, Maryland, United States
ME

Mark T. Esser, PhD

Phylogenetic and alpha toxin variant analyses of Staphylococcus aureus strains isolated from patient
AstraZeneca
Gaithersburg, Maryland, United States